The inaugural PharmAus showcase saw GSK and 19 other innovative pharmaceutical companies illustrate our industry’s investment and collaboration with Australia’s top research institutes, universities, biotechs and patients, to deliver the latest breakthroughs in treatment.
There is growing recognition that no single research body or group has the know-how or resources to tackle the most widespread and persistent diseases. Fortunately, a growing number of scientists are engaged in open source innovation that removes barriers and creates a more transparent environment for medical discovery.
New medicines are urgently needed for diseases of the developing world and those medicines need to be affordable.
Bioelectronic medicine is a vision far from today’s medical practice. But we believe that one day, tiny devices, smaller than grains of rice, could be used to restore health in a range of chronic diseases centred on organs and biological functions.
GSK has been a significant supporter of The George Institute for Global Health for a number of years and we’ve recently contributed $161,000 to support a research fellow in respiratory medicine.